These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Johnson LE; McNeel DG Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020 [TBL] [Abstract][Full Text] [Related]
6. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470 [TBL] [Abstract][Full Text] [Related]
7. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. Olson BM; Jankowska-Gan E; Becker JT; Vignali DA; Burlingham WJ; McNeel DG J Immunol; 2012 Dec; 189(12):5590-601. PubMed ID: 23152566 [TBL] [Abstract][Full Text] [Related]
8. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062 [TBL] [Abstract][Full Text] [Related]
10. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736 [TBL] [Abstract][Full Text] [Related]
11. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048 [TBL] [Abstract][Full Text] [Related]
12. An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Spies E; Reichardt W; Alvarez G; Groettrup M; Ohlschläger P Mol Ther; 2012 Mar; 20(3):555-64. PubMed ID: 22086231 [TBL] [Abstract][Full Text] [Related]
13. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model. Simons BW; Cannella F; Rowley DT; Viscidi RP Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503 [TBL] [Abstract][Full Text] [Related]
14. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. Johnson LE; Olson BM; McNeel DG J Immunother Cancer; 2017 Jul; 5(1):56. PubMed ID: 28716080 [TBL] [Abstract][Full Text] [Related]
16. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. McNeel DG; Becker JT; Eickhoff JC; Johnson LE; Bradley E; Pohlkamp I; Staab MJ; Liu G; Wilding G; Olson BM Clin Cancer Res; 2014 Jul; 20(14):3692-704. PubMed ID: 24850844 [TBL] [Abstract][Full Text] [Related]
17. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287 [TBL] [Abstract][Full Text] [Related]
18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
19. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328 [TBL] [Abstract][Full Text] [Related]
20. Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Johnson LE; Frye TP; McNeel DG Oncoimmunology; 2012 Dec; 1(9):1546-1556. PubMed ID: 23264901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]